Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review

JCO Precis Oncol. 2022 Jan:6:e2100437. doi: 10.1200/PO.21.00437.

Joanne Lundy^{1

2

3

4}, Owen McKay⁵, Daniel Croagh^{1

2

3}, Vinod Ganju^{4

6}

¹ Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
² Department of Molecular Translational Science, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.
³ Department of Surgery, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.
⁴ Peninsula and Southeast Oncology, Frankston, Victoria, Australia.
⁵ Department of Gastroenterology and Hepatology, Monash Health, Clayton, Victoria, Australia.
⁶ Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria, Australia.

No abstract available

Publication types